source
- Kodiak Sciences' eye disease drug matches Eylea in Phase 3, sending stock soaringKodiak Sciences reported that two of its eye‑disease candidates performed on par with aflibercept (Eylea) in a pivotal Phase 3 trial. The data suggest comparable efficacy in treating the targeted r…
- AI tools that aid vaccine design could also accelerate creation of bioweapons, warns former White House Covid adviserAshish K. Jha, a former White House Covid‑19 response coordinator and senior fellow at Harvard Kennedy School, cautions that artificial intelligence is lowering the barriers that kept biological we…